NASDAQ:INO - Inovio Pharmaceuticals, Inc.
$3.72
 $0.03
+0.82%
1:45PM EDT
2019-02-15
Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  INO     avg for
industry  
  avg for
sector  
42 stocks weight:  6. 41   0. 00   0. 00  
42 stocks rank:  3. 99 K 1. 86 K 1. 09 K
# analyst opinions:  6. 00   14. 92   14. 43  

quick ratio:  3. 21   5. 37   1. 81  
current ratio:  3. 34   5. 69   2. 19  

target price low:  8. 00   88. 97   117. 82  
target price avg:  10. 67   115. 19   141. 96  
target price high:  4. 14   143. 40   163. 16  
1-yr high:  6. 11   124. 30   142. 77  
last close:  3. 69   101. 85   127. 84  
50-day avg:  4. 71   98. 27   122. 46  
200-day avg:  4. 77   99. 72   122. 70  
1-yr low:  3. 69   78. 19   100. 16  
volume:  597. 41 K 2. 38 M 4. 64 M
50-day avg volume:  946. 21 K 3. 31 M 4. 94 M
200-day avg volume:  928. 73 K 3. 23 M 4. 28 M

1-day return:  -21. 15 % 0. 22 % 0. 48 %
this week return:  -19. 96 % 1. 77 % 2. 01 %
12-wk return:  -28. 63 % 6. 56 % 3. 33 %
52-wk return:  15. 56 % -2. 23 % 14. 35 %

enterprise value (EV):  360. 83 M 55. 17 B 104. 51 B
market cap:  351. 86 M 49. 01 B 96. 46 B
EBITDA:  -84. 25 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -4. 28   -91. 79   2. 29  
enterprise/revenue (EV/R):  9. 81   29. 84   23. 39  
total revenue:  36. 77 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -85. 51 M 2. 37 B 3. 58 B

shares outstanding:  95. 35 M 607. 99 M 1. 22 B
shares:  89. 55 M 605. 53 M 1. 15 B
shares short:  6. 44 M 11. 62 M 12. 55 M
shares short prior month:  5. 35 M 11. 95 M 13. 44 M
short ratio:  6. 83   4. 82   3. 10  
short % of float:  7. 58 % 6. 19 % 2. 82 %
total cash/share:  0. 90   12. 02   11. 46  
total cash:  85. 49 M 7. 41 B 7. 37 B
free cash flow:  -42. 25 M 95. 99 M 2. 04 B
operating cash flow:  -70. 22 M 164. 74 M 3. 04 B

book value:  1. 10   14. 43   28. 26  
price/book:  3. 36   -1. 57   -2. 97  
gross profits:  -56. 35 M 8. 28 B 18. 09 B
operating margins:  -240. 65 % -458. 01 % -642. 83 %
EBITDA margins:  -229. 16 % 13. 81 % 22. 47 %
profit margins:  -232. 58 % 6. 57 % 9. 92 %
gross margins:  -154. 40 % 49. 33 % 54. 53 %

1-yr max volatility:  -21. 15 % --- ---
1-yr mean volatility:  0. 01 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 94   3. 03   4. 09  
forward EPS:  -0. 98   4. 33   6. 99  
P/E:  -3. 91   6. 11   26. 91  
forward P/E:  -4. 70   8. 38   10. 48  
PE/G:  0. 16   0. 37   5. 61  
growth:  -24. 30 % 683. 72 % 104. 79 %
earnings high:  -0. 21   1. 27   1. 66  
earnings avg:  -0. 28   1. 01   1. 53  
earnings low:  -0. 30   0. 76   1. 40  
revenue high:  5. 15 M 2. 86 B 11. 19 B
revenue avg:  2. 39 M 2. 78 B 10. 84 B
revenue low:  1. 05 M 2. 67 B 10. 64 B
return on assets:  -32. 12 % -3. 27 % 3. 81 %
return on equity:  -64. 34 % 107. 48 % 27. 82 %
revenue growth:  -24. 30 % 648. 36 % 97. 70 %
revenue/share:  0. 40   14. 68   59. 83  

beta (1yr vs S&P500):  1. 24   1. 21   0. 93  
sharpe (1yr):  0. 05   0. 06   0. 98  

held % insiders:  6. 08 % 6. 46 % 3. 21 %
held % institutions:  35. 16 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : INO
.    + 0.977 =         0.977 :: INITIAL WEIGHT
.   + 161.62 =       162.597 :: inverse volume-to-price addition
.  + 484.154 =       646.751 :: spline projection addition
.  - 122.919 =       523.832 :: poor performance penalty
.    x 0.935 =       490.043 :: one-year gains+dividend factor
.    x 0.731 =       358.106 :: 13 weeks' performance factor
.    x 1.492 =       534.469 :: industry recommendation factor
.    x 1.329 =       710.273 :: EV/R factor
.    x 0.997 =       707.992 :: return on assets factor
.    x 0.994 =       703.437 :: return on equity factor
.    x 0.998 =       701.728 :: revenue growth factor
.    x 2.587 =      1815.477 :: current ratio factor
.    x 1.205 =      2187.845 :: quick ratio factor
.    x 1.071 =       2342.54 :: short ratio factor
.    x 2.034 =      4763.877 :: price-to-book factor
.    x 2.152 =     10250.873 :: P/E weight
.    x 1.579 =     16186.346 :: PE/G factor
.    x 1.618 =     26195.121 :: beta factor
.    x 0.053 =      1390.532 :: sharpe factor
.    x 2.223 =      3091.534 :: target low factor
.    x 1.458 =      4508.852 :: target mean factor
.    x 1.035 =      4665.962 :: target high factor
.    x 1.066 =      4972.109 :: industry 12-weeks return
.    x 0.757 =      3762.725 :: "drift" penalty 5 days ago
.    x 0.946 =      3557.929 :: overall "drift" factor
.    x 0.999 =      3554.671 :: largest single-day jump factor
.    x 0.074 =       263.504 :: low price factor
.      x 1.0 =       263.522 :: factor hist industry gain for week 06
.   cubeRoot =         6.411 :: reduced for readability
.                      6.411 :: FINAL WEIGHT for NASDAQ:INO


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org